Sumitomo Dainippon updates on candidates; Daiichi Sankyo reports post-Ranbaxy;

> Japan's Sumitomo Dainippon Pharma updated its pipeline in quarterly results on July 29, showing candidate EPI-743 to treat Leigh syndrome meeting its primary endpoint in a Phase II/III trial in Japan. But the trial showed no statistical difference compared to the primary endpoint in a Phase IIb placebo-controlled trial by U.S.-based Edison Pharmaceuticals, and the company will review its next steps. The company also said it would proceed on further trials of EPI-589 to treat Parkinson's disease and amyotrophic lateral sclerosis, with Japan and North America development and marketing rights acquired from Edison. Release (PDF)

> Taiwan's TWi Biotechnology said it has received Notices of Allowance for lead candidate AC-201, a first-in-class small molecule, from the European Patent Office and the Patent Office of the Russian Federation. Release

> India's Dr. Reddy's Laboratories said consolidated net profit for the quarter ended June rose 14% to 6.26 billion rupees ($97.8 million). Release (PDF)

> Japan's Eisai and San Diego-based Halozyme Therapeutics ($HALO) signed a clinical collaboration agreement to evaluate Eisai's agent eribulin mesylate (Halaven) in combination with Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) in first-line HER2-negative metastatic breast cancer. Release

> Japan's Daiichi Sankyo reported a net profit of ¥34.93 billion ($281.67 million) in the first quarter, up 74.8% as the Ranbaxy sale was included. "In the first three months of fiscal 2014, the Ranbaxy Group was classified as a discontinued operation," the company said in a release. "Consequently, the amounts of revenue, operating profit and profit before tax have been restated and indicated as only the values for continuing operations excluding the Ranbaxy Group are indicated." Release (PDF)

> India's Health Minister, J.P. Nadda, said the country has 2.6 million cases of tuberculosis, citing World Health Organization data, the Economic Times reports, as the country undertakes its own survey on patients with drug-resistant TB. Report

> San Diego-based ResMed will buy China-focused and privately held Curative Medical, a provider of noninvasive ventilation and sleep-disordered breathing medical devices and accessories, for an undisclosed amount. Curative has manufacturing operations in Suzhou and offices in Beijing, Germany and the U.S., which will retain operational independence after the transaction, which is expected to close in the fourth quarter. Release